BR0111427A - Modificação de cristal - Google Patents

Modificação de cristal

Info

Publication number
BR0111427A
BR0111427A BR0111427-1A BR0111427A BR0111427A BR 0111427 A BR0111427 A BR 0111427A BR 0111427 A BR0111427 A BR 0111427A BR 0111427 A BR0111427 A BR 0111427A
Authority
BR
Brazil
Prior art keywords
crystal modification
benzenoacetic
hydroxydiphenylmethyl
piperidinyl
hydroxy
Prior art date
Application number
BR0111427-1A
Other languages
English (en)
Inventor
Julian Anthony Davies
James Edward Gano
Original Assignee
Geneva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneva Pharmaceuticals Inc filed Critical Geneva Pharmaceuticals Inc
Publication of BR0111427A publication Critical patent/BR0111427A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MODIFICAçãO DE CRISTAL". A presente invenção refere-se a uma nova forma de cristal do composto de cloridrato de ácido <244>,<244>-dimetil-4-{1-hidróxi-4-(4-(hidroxidifenilmetil)-1-piperidinil} -butil}-benzenoacético, a um processo para sua preparação e ao seu uso farmacêutico.
BR0111427-1A 2000-06-06 2001-06-06 Modificação de cristal BR0111427A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/588,391 US6613906B1 (en) 2000-06-06 2000-06-06 Crystal modification
PCT/US2001/018306 WO2001094313A2 (en) 2000-06-06 2001-06-06 Crystal modification of fexofenadine

Publications (1)

Publication Number Publication Date
BR0111427A true BR0111427A (pt) 2004-12-07

Family

ID=24353650

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111427-1A BR0111427A (pt) 2000-06-06 2001-06-06 Modificação de cristal

Country Status (14)

Country Link
US (2) US6613906B1 (pt)
EP (1) EP1320524A2 (pt)
KR (1) KR20030016282A (pt)
AU (2) AU6537701A (pt)
BR (1) BR0111427A (pt)
CA (1) CA2410227A1 (pt)
CZ (1) CZ20023962A3 (pt)
HR (1) HRP20020972A2 (pt)
IL (1) IL153171A0 (pt)
MX (1) MXPA02012119A (pt)
NZ (1) NZ522940A (pt)
SK (1) SK17012002A3 (pt)
WO (1) WO2001094313A2 (pt)
ZA (1) ZA200209873B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
AU693892B2 (en) * 1994-05-18 1998-07-09 Aventisub Ii Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
CH695216A5 (de) * 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
CA2444456A1 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
US8263124B2 (en) 2002-04-04 2012-09-11 Dr. Reddy's Laboratories Limited Anthistamine-decongestant pharmaceutical compositions
WO2003104197A1 (en) * 2002-06-10 2003-12-18 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
GB0319935D0 (en) * 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
MXPA06012281A (es) * 2004-04-26 2007-07-18 Teva Pharma Formas cristalinas de clorhidrato de fexofenadina y procesos para su preparacion.
WO2007052310A2 (en) * 2005-11-03 2007-05-10 Morepen Laboratories Limited Polymorphs of fexofenadine hydrochloride and process for their preparation
US20080095843A1 (en) * 2006-07-11 2008-04-24 Nutalapati Siva R K Controlled-release formulations
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US5631375A (en) 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
WO1995000482A1 (en) 1993-06-24 1995-01-05 Albany Molecular Research, Inc. Piperidine derivatives and process for their production
CN1159277C (zh) 1993-06-25 2004-07-28 默里尔药物公司 用于制备抗组胺哌啶衍生物的新中间体
AU693892B2 (en) 1994-05-18 1998-07-09 Aventisub Ii Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharma Inc Arzneizubereitungen für piperidinalkanolderivate
US5574045A (en) 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
FR2776302B1 (fr) 1998-03-19 2002-04-12 Hoechst Marion Roussel Inc Nouveau procede de preparation de la fexofenadine
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
IN191492B (pt) 1999-05-25 2003-12-06 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
AU2001265377B2 (en) 2004-02-26
CA2410227A1 (en) 2001-12-13
EP1320524A2 (en) 2003-06-25
SK17012002A3 (sk) 2003-06-03
WO2001094313A2 (en) 2001-12-13
KR20030016282A (ko) 2003-02-26
AU6537701A (en) 2001-12-17
CZ20023962A3 (cs) 2003-05-14
MXPA02012119A (es) 2004-08-19
WO2001094313A3 (en) 2002-04-04
IL153171A0 (en) 2003-06-24
HRP20020972A2 (en) 2005-02-28
US20030212108A1 (en) 2003-11-13
US6613906B1 (en) 2003-09-02
ZA200209873B (en) 2003-09-29
NZ522940A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
BR0111427A (pt) Modificação de cristal
CA2296604A1 (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
BG66094B1 (bg) Азабициклени съединения, тяхното получаване и използване като лекарствени средста, по-специално като антибактериални средства
ATE259779T1 (de) Formoterol-polymorphe
BR0013184A (pt) Amidas de ácido carboxìlico, composições farmacêuticas contendo estes compostos, uso e preparação destes
HRP20050070B1 (hr) 3-2-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primjena kao farmaceutskog pripravka
BR0213380A (pt) Derivados propiÈnicos alfa-oxissubstituìdos por beta-fenila: processo para sua preparação e seu uso na preparação de compostos farmaceuticamente importantes
BR0213931A (pt) Forma polimórfica de rimonabant, processo para sua preparação e composições farmacêuticas contendo-as
EE200100335A (et) 4-(aminometüül)piperidiinbensamiidid, vaheühendid, farmatseutiline kompositsioon ja nende valmistamismeetodid
BR9806568A (pt) Forma de cristal de n-(4-trifluormetilfenil)-5-metilisoxazol-4-carboxamida
BR0101230A (pt) Processo para a preparação de11-amino-3-cloro-6,11-diidro-5-5-dioxo-6-metil-dibenzo[c,f][1,2]tiazepina e aplicação para a sìntese detianeptina
BR9908458A (pt) Tiolésteres de ácido 11beta-benzaldoxim-estra-4,9-dien-carbÈnico substituìdos por s, processos para a sua preparação e preparados farmacêuticos contendo estes compostos
BR0113650A (pt) N-(3,5-dicloro-2-metoxifenil)-4-metóxi-3-piperazina-1-il a-benzenossulfonamida
BR0214742A (pt) Polimorfo cristalino de cloridrato de venlafaxina e métodos para sua preparação
BR0106248A (pt) Inibidores de metaloprotease, processo para a sua preparação e composições farmacêuticas contendo os mesmos
SI1260505T1 (en) A process for the preparation of 4-(1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl)-alpha, alpha-dimethylbenzeneacetic acid
BR9910020A (pt) Derivados do ácido octa-hidros-6,10-dioxo-6h-piridazino(1,2-a)(1,2)diazepi na-1-carboxìlico, seu processo de preparação e sua aplicação à preparação de compostos terapeuticamente ativos
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
PT1246790E (pt) Bases de mannich de 1- e 2-naftol substituido
BR0207867A (pt) Sal de benzoilguanidina
HUP0105307A3 (en) Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors and pharmaceutical compositions thereof and process for preparation the compounds
BR0012493B1 (pt) processo para a preparação de um composto de éster de ácido 2-hidróxi-benzóico substituìdo, e, processo para a manufatura de composto fungicida de benzofenona.
BR0113732A (pt) Forma polimórfica da 17-beta-(n-ter. butil carbamoil)-4-aza-5-alfa-androst-1-en-3-ona e processo para sua preparação
BR9906931A (pt) Triazepinonas, processo para sua preparação e sua aplicação terapêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009.